Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial (vol 9, 22, 2016)

Foss, F; Horwitz, S; Pro, B; Prince, HM; Sokol, L; Balser, B; Wolfson, J; Coiffier, B

Download

published version (404.6Kb)

Citations

Scopus

Web of Science

Altmetric

Author

Foss, F; Horwitz, S; Pro, B; Prince, HM; Sokol, L; Balser, B; Wolfson, J; Coiffier, B

Date

2017-09-18

Source Title

Journal of Hematology and Oncology

Publisher

BIOMED CENTRAL LTD

University of Melbourne Author/s

Prince, Henry

Affiliation

Medicine (St Vincent's)

Metadata

Show full item record

Document Type

Journal Article

Citations

Foss, F., Horwitz, S., Pro, B., Prince, H. M., Sokol, L., Balser, B., Wolfson, J. & Coiffier, B. (2017). Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial (vol 9, 22, 2016). JOURNAL OF HEMATOLOGY & ONCOLOGY, 10 (1), https://doi.org/10.1186/s13045-017-0518-8.

Access Status

Open Access